Nader Hanna
Family Medicine · Bronx, NYNPI 1043434731
Payments from drug & device makers
Across 425 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Merck$1K
- AstraZeneca$855
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$620
- Amgen$427
- Novo Nordisk$423
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,91499%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $2,233 |
| Merck | 50 | $1,013 |
| AstraZeneca | 49 | $855 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $620 |
| Amgen(2 entities) | 24 | $427 |
| Novo Nordisk | 23 | $423 |
| Ardelyx, Inc. | 15 | $351 |
| Kowa Pharmaceuticals America, Inc. | 20 | $309 |
| Phathom Pharmaceuticals, Inc. | 2 | $286 |
| GSK | 6 | $232 |
| Sanofi-aventis U.S. LLC | 12 | $229 |
| Pfizer | 9 | $206 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $175 |
| Lilly USA, LLC | 9 | $159 |
| Shield Therapeutics Inc | 7 | $148 |
| Bayer | 7 | $140 |
| Boehringer Ingelheim | 5 | $137 |
| Johnson & Johnson | 3 | $137 |
| Medtronic(2 entities) | 7 | $132 |
| Intra-sana Laboratories | 4 | $98 |
| Abbott | 5 | $89 |
| Abiomed | 1 | $84 |
| Nestle Healthcare Nutrition Inc. | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| Lundbeck LLC | 2 | $57 |
| Redhill Biopharma Inc. | 2 | $51 |
| Corcept Therapeutics | 2 | $46 |
| Organon | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Gilead | 1 | $26 |
| United Therapeutics Corporation | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$647
- VOQUEZNA$286
- TRELEGY ELLIPTA$125
- INVOKANA$103
How this compares
$8,960 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 210 | $149,746 |
| JanumetSitagliptin Phos/Metformin Hcl | 131 | $76,822 |
| OzempicSemaglutide | 70 | $70,268 |
| EntrestoSacubitril/Valsartan | 74 | $65,941 |
| JardianceEmpagliflozin | 76 | $59,629 |
| Diclofenac Potassium | 111 | $58,344 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 76 | $44,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $38,623 |
| EliquisApixaban | 52 | $34,120 |
| Metformin Hcl | 225 | $33,635 |
| Diclofenac Sodium | 155 | $28,859 |
| QuliptaAtogepant | 26 | $27,280 |
| JanuviaSitagliptin Phosphate | 30 | $25,299 |
| LinzessLinaclotide | 49 | $24,748 |
| TrulicityDulaglutide | 19 | $20,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $855 | $159,675250 claims |
| MerckJanumet, Januvia, Verquvo, Janumet Xr | $1,013 | $115,606191 claims |
| Boehringer IngelheimJardiance, Jentadueto, Synjardy | $137 | $89,659132 claims |
| AbbVieQulipta, Linzess, Vraylar | $2,233 | $70,33388 claims |
| Novo NordiskOzempic | $423 | $70,26870 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $232 | $48,92989 claims |
| PfizerEliquis | $206 | $34,12052 claims |
| Lilly USA, LLCTrulicity | $159 | $20,62919 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $286 | $15,62914 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $229 | $9,07211 claims |
| BayerKerendia | $140 | $8,43214 claims |
| Johnson & JohnsonXarelto | $137 | $7,66314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.